| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1355771 | Bioorganic Chemistry | 2011 | 5 Pages |
Current state of medical sciences does not allow to treatment neurodegenerative diseases such as Alzheimer’s disease (AD). At present treatment of AD is severely restricted. The main class of medicines which are applied in AD is acetylcholinesterase inhibitors (AChEIs) like tacrine, donepezil, galantamine and rivastigmine that do not contribute to significant and long-term improvement in cognitive and behavioural functions.In this work, we report synthesis and biological evaluation of new hybrids of tacrine-6-hydrazinonicotinamide. The synthesis was based on the condensation reaction between tacrine derivatives and the hydrazine nicotinate moiety (HYNIC). All obtained compounds present affinity for both cholinesterases and are characterized by high selectivity in relation to butyrylcholinesterase (BChE).
Graphical abstractSynthesis of tetrahydroacridine as acetylcholinesterase inhibitors.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Acetylcholinesterase inhibitors in treatment of Alzheimer’s disease. ► Synthesis of new hybrids of 6-hydrazinonicotinic acid and tacrine derivatives. ► Evaluation of acetylcholinesterase activity of newly synthesized compounds. ► Estimation of selectivity of obtained molecules towards acetylcholinesterases.
